Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate the safety a...
Saved in:
| Published in | The Lancet (British edition) Vol. 383; no. 9911; pp. 60 - 68 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier Ltd
04.01.2014
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate the safety and efficacy of ALN-PCS, a small interfering RNA that inhibits PCSK9 synthesis, in healthy volunteers with raised cholesterol who were not on lipid-lowering treatment.
We did a randomised, single-blind, placebo-controlled, phase 1 dose-escalation study in healthy adult volunteers with serum LDL cholesterol of 3·00 mmol/L or higher. Participants were randomly assigned in a 3:1 ratio by computer algorithm to receive one dose of intravenous ALN-PCS (with doses ranging from 0·015 to 0·400 mg/kg) or placebo. The primary endpoint was safety and tolerability of ALN-PCS. Secondary endpoints were the pharmacokinetic characteristics of ALN-PCS and its pharmacodynamic effects on PCSK9 and LDL cholesterol. Study participants were masked to treatment assignment. Analysis was per protocol and we used ANCOVA to analyse pharmacodynamic endpoint data. This trial is registered with ClinicalTrials.gov, number NCT01437059.
Of 32 participants, 24 were randomly allocated to receive a single dose of ALN-PCS (0·015 mg/kg [n=3], 0·045 mg/kg [n=3], 0·090 mg/kg [n=3], 0·150 mg/kg [n=3], 0·250 mg/kg [n=6], or 0·400 mg/kg [n=6]) and eight to placebo. The proportions of patients affected by treatment-emergent adverse events were similar in the ALN-PCS and placebo groups (19 [79%] vs seven [88%]). ALN-PCS was rapidly distributed, with peak concentration and area under the curve (0 to last measurement) increasing in a roughly dose-proportional way across the dose range tested. In the group given 0·400 mg/kg of ALN-PCS, treatment resulted in a mean 70% reduction in circulating PCSK9 plasma protein (p<0·0001) and a mean 40% reduction in LDL cholesterol from baseline relative to placebo (p<0·0001).
Our results suggest that inhibition of PCSK9 synthesis by RNA interference (RNAi) provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol. These results support the further assessment of ALN-PCS in patients with hypercholesterolaemia, including those being treated with statins. This study is the first to show an RNAi drug being used to affect a clinically validated endpoint (ie, LDL cholesterol) in human beings.
Alnylam Pharmaceuticals. |
|---|---|
| AbstractList | Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate the safety and efficacy of ALN-PCS, a small interfering RNA that inhibits PCSK9 synthesis, in healthy volunteers with raised cholesterol who were not on lipid-lowering treatment.
We did a randomised, single-blind, placebo-controlled, phase 1 dose-escalation study in healthy adult volunteers with serum LDL cholesterol of 3·00 mmol/L or higher. Participants were randomly assigned in a 3:1 ratio by computer algorithm to receive one dose of intravenous ALN-PCS (with doses ranging from 0·015 to 0·400 mg/kg) or placebo. The primary endpoint was safety and tolerability of ALN-PCS. Secondary endpoints were the pharmacokinetic characteristics of ALN-PCS and its pharmacodynamic effects on PCSK9 and LDL cholesterol. Study participants were masked to treatment assignment. Analysis was per protocol and we used ANCOVA to analyse pharmacodynamic endpoint data. This trial is registered with ClinicalTrials.gov, number NCT01437059.
Of 32 participants, 24 were randomly allocated to receive a single dose of ALN-PCS (0·015 mg/kg [n=3], 0·045 mg/kg [n=3], 0·090 mg/kg [n=3], 0·150 mg/kg [n=3], 0·250 mg/kg [n=6], or 0·400 mg/kg [n=6]) and eight to placebo. The proportions of patients affected by treatment-emergent adverse events were similar in the ALN-PCS and placebo groups (19 [79%] vs seven [88%]). ALN-PCS was rapidly distributed, with peak concentration and area under the curve (0 to last measurement) increasing in a roughly dose-proportional way across the dose range tested. In the group given 0·400 mg/kg of ALN-PCS, treatment resulted in a mean 70% reduction in circulating PCSK9 plasma protein (p<0·0001) and a mean 40% reduction in LDL cholesterol from baseline relative to placebo (p<0·0001).
Our results suggest that inhibition of PCSK9 synthesis by RNA interference (RNAi) provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol. These results support the further assessment of ALN-PCS in patients with hypercholesterolaemia, including those being treated with statins. This study is the first to show an RNAi drug being used to affect a clinically validated endpoint (ie, LDL cholesterol) in human beings.
Alnylam Pharmaceuticals. Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate the safety and efficacy of ALN-PCS, a small interfering RNA that inhibits PCSK9 synthesis, in healthy volunteers with raised cholesterol who were not on lipid-lowering treatment. Methods We did a randomised, single-blind, placebo-controlled, phase 1 dose-escalation study in healthy adult volunteers with serum LDL cholesterol of 3 times 00 mmol/L or higher. Participants were randomly assigned in a 3:1 ratio by computer algorithm to receive one dose of intravenous ALN-PCS (with doses ranging from 0 times 015 to 0 times 400 mg/kg) or placebo. The primary endpoint was safety and tolerability of ALN-PCS. Secondary endpoints were the pharmacokinetic characteristics of ALN-PCS and its pharmacodynamic effects on PCSK9 and LDL cholesterol. Study participants were masked to treatment assignment. Analysis was per protocol and we used ANCOVA to analyse pharmacodynamic endpoint data. This trial is registered with ClinicalTrials.gov, number NCT01437059. Findings Of 32 participants, 24 were randomly allocated to receive a single dose of ALN-PCS (0 times 015 mg/kg [n=3], 0 times 045 mg/kg [n=3], 0 times 090 mg/kg [n=3], 0 times 150 mg/kg [n=3], 0 times 250 mg/kg [n=6], or 0 times 400 mg/kg [n=6]) and eight to placebo. The proportions of patients affected by treatment-emergent adverse events were similar in the ALN-PCS and placebo groups (19 [79%] seven [88%]). ALN-PCS was rapidly distributed, with peak concentration and area under the curve (0 to last measurement) increasing in a roughly dose-proportional way across the dose range tested. In the group given 0 times 400 mg/kg of ALN-PCS, treatment resulted in a mean 70% reduction in circulating PCSK9 plasma protein (p<0 times 0001) and a mean 40% reduction in LDL cholesterol from baseline relative to placebo (p<0 times 0001). Interpretation Our results suggest that inhibition of PCSK9 synthesis by RNA interference (RNAi) provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol. These results support the further assessment of ALN-PCS in patients with hypercholesterolaemia, including those being treated with statins. This study is the first to show an RNAi drug being used to affect a clinically validated endpoint (ie, LDL cholesterol) in human beings. Funding Alnylam Pharmaceuticals. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate the safety and efficacy of ALN-PCS, a small interfering RNA that inhibits PCSK9 synthesis, in healthy volunteers with raised cholesterol who were not on lipid-lowering treatment.BACKGROUNDProprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate the safety and efficacy of ALN-PCS, a small interfering RNA that inhibits PCSK9 synthesis, in healthy volunteers with raised cholesterol who were not on lipid-lowering treatment.We did a randomised, single-blind, placebo-controlled, phase 1 dose-escalation study in healthy adult volunteers with serum LDL cholesterol of 3·00 mmol/L or higher. Participants were randomly assigned in a 3:1 ratio by computer algorithm to receive one dose of intravenous ALN-PCS (with doses ranging from 0·015 to 0·400 mg/kg) or placebo. The primary endpoint was safety and tolerability of ALN-PCS. Secondary endpoints were the pharmacokinetic characteristics of ALN-PCS and its pharmacodynamic effects on PCSK9 and LDL cholesterol. Study participants were masked to treatment assignment. Analysis was per protocol and we used ANCOVA to analyse pharmacodynamic endpoint data. This trial is registered with ClinicalTrials.gov, number NCT01437059.METHODSWe did a randomised, single-blind, placebo-controlled, phase 1 dose-escalation study in healthy adult volunteers with serum LDL cholesterol of 3·00 mmol/L or higher. Participants were randomly assigned in a 3:1 ratio by computer algorithm to receive one dose of intravenous ALN-PCS (with doses ranging from 0·015 to 0·400 mg/kg) or placebo. The primary endpoint was safety and tolerability of ALN-PCS. Secondary endpoints were the pharmacokinetic characteristics of ALN-PCS and its pharmacodynamic effects on PCSK9 and LDL cholesterol. Study participants were masked to treatment assignment. Analysis was per protocol and we used ANCOVA to analyse pharmacodynamic endpoint data. This trial is registered with ClinicalTrials.gov, number NCT01437059.Of 32 participants, 24 were randomly allocated to receive a single dose of ALN-PCS (0·015 mg/kg [n=3], 0·045 mg/kg [n=3], 0·090 mg/kg [n=3], 0·150 mg/kg [n=3], 0·250 mg/kg [n=6], or 0·400 mg/kg [n=6]) and eight to placebo. The proportions of patients affected by treatment-emergent adverse events were similar in the ALN-PCS and placebo groups (19 [79%] vs seven [88%]). ALN-PCS was rapidly distributed, with peak concentration and area under the curve (0 to last measurement) increasing in a roughly dose-proportional way across the dose range tested. In the group given 0·400 mg/kg of ALN-PCS, treatment resulted in a mean 70% reduction in circulating PCSK9 plasma protein (p<0·0001) and a mean 40% reduction in LDL cholesterol from baseline relative to placebo (p<0·0001).FINDINGSOf 32 participants, 24 were randomly allocated to receive a single dose of ALN-PCS (0·015 mg/kg [n=3], 0·045 mg/kg [n=3], 0·090 mg/kg [n=3], 0·150 mg/kg [n=3], 0·250 mg/kg [n=6], or 0·400 mg/kg [n=6]) and eight to placebo. The proportions of patients affected by treatment-emergent adverse events were similar in the ALN-PCS and placebo groups (19 [79%] vs seven [88%]). ALN-PCS was rapidly distributed, with peak concentration and area under the curve (0 to last measurement) increasing in a roughly dose-proportional way across the dose range tested. In the group given 0·400 mg/kg of ALN-PCS, treatment resulted in a mean 70% reduction in circulating PCSK9 plasma protein (p<0·0001) and a mean 40% reduction in LDL cholesterol from baseline relative to placebo (p<0·0001).Our results suggest that inhibition of PCSK9 synthesis by RNA interference (RNAi) provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol. These results support the further assessment of ALN-PCS in patients with hypercholesterolaemia, including those being treated with statins. This study is the first to show an RNAi drug being used to affect a clinically validated endpoint (ie, LDL cholesterol) in human beings.INTERPRETATIONOur results suggest that inhibition of PCSK9 synthesis by RNA interference (RNAi) provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol. These results support the further assessment of ALN-PCS in patients with hypercholesterolaemia, including those being treated with statins. This study is the first to show an RNAi drug being used to affect a clinically validated endpoint (ie, LDL cholesterol) in human beings.Alnylam Pharmaceuticals.FUNDINGAlnylam Pharmaceuticals. Summary Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate the safety and efficacy of ALN-PCS, a small interfering RNA that inhibits PCSK9 synthesis, in healthy volunteers with raised cholesterol who were not on lipid-lowering treatment. Methods We did a randomised, single-blind, placebo-controlled, phase 1 dose-escalation study in healthy adult volunteers with serum LDL cholesterol of 3·00 mmol/L or higher. Participants were randomly assigned in a 3:1 ratio by computer algorithm to receive one dose of intravenous ALN-PCS (with doses ranging from 0·015 to 0·400 mg/kg) or placebo. The primary endpoint was safety and tolerability of ALN-PCS. Secondary endpoints were the pharmacokinetic characteristics of ALN-PCS and its pharmacodynamic effects on PCSK9 and LDL cholesterol. Study participants were masked to treatment assignment. Analysis was per protocol and we used ANCOVA to analyse pharmacodynamic endpoint data. This trial is registered with ClinicalTrials.gov , number NCT01437059. Findings Of 32 participants, 24 were randomly allocated to receive a single dose of ALN-PCS (0·015 mg/kg [n=3], 0·045 mg/kg [n=3], 0·090 mg/kg [n=3], 0·150 mg/kg [n=3], 0·250 mg/kg [n=6], or 0·400 mg/kg [n=6]) and eight to placebo. The proportions of patients affected by treatment-emergent adverse events were similar in the ALN-PCS and placebo groups (19 [79%] vs seven [88%]). ALN-PCS was rapidly distributed, with peak concentration and area under the curve (0 to last measurement) increasing in a roughly dose-proportional way across the dose range tested. In the group given 0·400 mg/kg of ALN-PCS, treatment resulted in a mean 70% reduction in circulating PCSK9 plasma protein (p<0·0001) and a mean 40% reduction in LDL cholesterol from baseline relative to placebo (p<0·0001). Interpretation Our results suggest that inhibition of PCSK9 synthesis by RNA interference (RNAi) provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol. These results support the further assessment of ALN-PCS in patients with hypercholesterolaemia, including those being treated with statins. This study is the first to show an RNAi drug being used to affect a clinically validated endpoint (ie, LDL cholesterol) in human beings. Funding Alnylam Pharmaceuticals. Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations inPCSK9result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate the safety and efficacy of ALN-PCS, a small interfering RNA that inhibits PCSK9 synthesis, in healthy volunteers with raised cholesterol who were not on lipid-lowering treatment. Methods We did a randomised, single-blind, placebo-controlled, phase 1 dose-escalation study in healthy adult volunteers with serum LDL cholesterol of 3·00 mmol/L or higher. Participants were randomly assigned in a 3:1 ratio by computer algorithm to receive one dose of intravenous ALN-PCS (with doses ranging from 0·015 to 0·400 mg/kg) or placebo. The primary endpoint was safety and tolerability of ALN-PCS. Secondary endpoints were the pharmacokinetic characteristics of ALN-PCS and its pharmacodynamic effects on PCSK9 and LDL cholesterol. Study participants were masked to treatment assignment. Analysis was per protocol and we used ANCOVA to analyse pharmacodynamic endpoint data. This trial is registered withClinicalTrials.gov, numberNCT01437059. Findings Of 32 participants, 24 were randomly allocated to receive a single dose of ALN-PCS (0·015 mg/kg [n=3], 0·045 mg/kg [n=3], 0·090 mg/kg [n=3], 0·150 mg/kg [n=3], 0·250 mg/kg [n=6], or 0·400 mg/kg [n=6]) and eight to placebo. The proportions of patients affected by treatment-emergent adverse events were similar in the ALN-PCS and placebo groups (19 [79%]vsseven [88%]). ALN-PCS was rapidly distributed, with peak concentration and area under the curve (0 to last measurement) increasing in a roughly dose-proportional way across the dose range tested. In the group given 0·400 mg/kg of ALN-PCS, treatment resulted in a mean 70% reduction in circulating PCSK9 plasma protein (p<0·0001) and a mean 40% reduction in LDL cholesterol from baseline relative to placebo (p<0·0001). Interpretation Our results suggest that inhibition of PCSK9 synthesis by RNA interference (RNAi) provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol. These results support the further assessment of ALN-PCS in patients with hypercholesterolaemia, including those being treated with statins. This study is the first to show an RNAi drug being used to affect a clinically validated endpoint (ie, LDL cholesterol) in human beings. Funding Alnylam Pharmaceuticals. Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate the safety and efficacy of ALN-PCS, a small interfering RNA that inhibits PCSK9 synthesis, in healthy volunteers with raised cholesterol who were not on lipid-lowering treatment. Methods: We did a randomised, single-blind, placebo-controlled, phase 1 dose-escalation study in healthy adult volunteers with serum LDL cholesterol of 3·00 mmol/L or higher. Participants were randomly assigned in a 3:1 ratio by computer algorithm to receive one dose of intravenous ALN-PCS (with doses ranging from 0·015 to 0·400 mg/kg) or placebo. The primary endpoint was safety and tolerability of ALN-PCS. Secondary endpoints were the pharmacokinetic characteristics of ALN-PCS and its pharmacodynamic effects on PCSK9 and LDL cholesterol. Study participants were masked to treatment assignment. Analysis was per protocol and we used ANCOVA to analyse pharmacodynamic endpoint data. This trial is registered with ClinicalTrials.gov, number NCT01437059. Findings: Of 32 participants, 24 were randomly allocated to receive a single dose of ALN-PCS (0·015 mg/kg [n=3], 0·045 mg/kg [n=3], 0·090 mg/kg [n=3], 0·150 mg/kg [n=3], 0·250 mg/kg [n=6], or 0·400 mg/kg [n=6]) and eight to placebo. The proportions of patients affected by treatment-emergent adverse events were similar in the ALN-PCS and placebo groups (19 [79%] vs seven [88%]). ALN-PCS was rapidly distributed, with peak concentration and area under the curve (0 to last measurement) increasing in a roughly dose-proportional way across the dose range tested. In the group given 0·400 mg/kg of ALN-PCS, treatment resulted in a mean 70% reduction in circulating PCSK9 plasma protein (p<0·0001) and a mean 40% reduction in LDL cholesterol from baseline relative to placebo (p<0·0001). Interpretation: Our results suggest that inhibition of PCSK9 synthesis by RNA interference (RNAi) provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol. These results support the further assessment of ALN-PCS in patients with hypercholesterolaemia, including those being treated with statins. This study is the first to show an RNAi drug being used to affect a clinically validated endpoint (ie, LDL cholesterol) in human beings. |
| Author | Cehelsky, Jeffrey Liebow, Abigail Frank-Kamenetsky, Maria Shulga-Morskaya, Svetlana Vaishnaw, Akshay K Simon, Amy Sutherland, Jessica E Kotelianski, Victor Fitzgerald, Kevin Chiesa, Joseph Clausen, Valerie A Karsten, Verena Nochur, Saraswathy V Horton, Jay Hutabarat, Renta M Mant, Timothy Munisamy, Malathy Gollob, Jared A Bettencourt, Brian R Ritter, James |
| Author_xml | – sequence: 1 givenname: Kevin surname: Fitzgerald fullname: Fitzgerald, Kevin email: kfitzgerald@alnylam.com organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 2 givenname: Maria surname: Frank-Kamenetsky fullname: Frank-Kamenetsky, Maria organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 3 givenname: Svetlana surname: Shulga-Morskaya fullname: Shulga-Morskaya, Svetlana organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 4 givenname: Abigail surname: Liebow fullname: Liebow, Abigail organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 5 givenname: Brian R surname: Bettencourt fullname: Bettencourt, Brian R organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 6 givenname: Jessica E surname: Sutherland fullname: Sutherland, Jessica E organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 7 givenname: Renta M surname: Hutabarat fullname: Hutabarat, Renta M organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 8 givenname: Valerie A surname: Clausen fullname: Clausen, Valerie A organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 9 givenname: Verena surname: Karsten fullname: Karsten, Verena organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 10 givenname: Jeffrey surname: Cehelsky fullname: Cehelsky, Jeffrey organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 11 givenname: Saraswathy V surname: Nochur fullname: Nochur, Saraswathy V organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 12 givenname: Victor surname: Kotelianski fullname: Kotelianski, Victor organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 13 givenname: Jay surname: Horton fullname: Horton, Jay organization: Internal Medicine and Molecular Genetics, University of Texas South Western, Dallas, TX, USA – sequence: 14 givenname: Timothy surname: Mant fullname: Mant, Timothy organization: Quintiles Drug Research Unit at Guy's Hospital, London, UK – sequence: 15 givenname: Joseph surname: Chiesa fullname: Chiesa, Joseph organization: Covance Clinical Research Unit, Leeds, UK – sequence: 16 givenname: James surname: Ritter fullname: Ritter, James organization: Quintiles Drug Research Unit at Guy's Hospital, London, UK – sequence: 17 givenname: Malathy surname: Munisamy fullname: Munisamy, Malathy organization: Covance Clinical Research Unit, Leeds, UK – sequence: 18 givenname: Akshay K surname: Vaishnaw fullname: Vaishnaw, Akshay K organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 19 givenname: Jared A surname: Gollob fullname: Gollob, Jared A organization: Alnylam Pharmaceuticals, Cambridge, MA, USA – sequence: 20 givenname: Amy surname: Simon fullname: Simon, Amy organization: Alnylam Pharmaceuticals, Cambridge, MA, USA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28036945$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24094767$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk31r1TAUxoso7kU_ghIQYQPrkjZNG8XJmPMFLypOwf9C2p7uZstNrkl78X5rP4Kn9-5FB7JB4bTkOb_zkqdbyV3nHSTJI0afM8rE3jFlnKaizMUOy3cFk4ynxZ1kk_ESX3j5426yeSnZSLZiPKWUckGL-8lGxqnkpSg3k99HXQdNT3xHtCNfPx0Q43oIHQRwDZA2DCfEO9JPgcSlwxBNHMXz4PHpwTjSeLeA0OuIkqHujTXRuL0z-IVn_XIORJKdL4fHH-UulmhXKExpwPVB9wbhiIsQhhmZvJmQZuotRGzBW2yFTEHbfrokC28HbAxCfEE0CQjyMxOhfUaw2ImFtLbG4dfc6gZqn2KFHhF2VMynY2-M9MFo-yC512kb4eF53E6-vz36dvg-nXx-9-HwYJI2osj7tNZFy-pCVHklZMW7opUd5VlHWVfztsszXcu6lkLmFRcSqqouWCcL2tZUAC3qfDvZX3PnQz2Ddj2uVfNgZjoslddG_XvizFSd-IXieVXi_SFg5xwQ_M8BV6Jw4Aas1Q78EBUraJFnJYabpVxmosikELeR0hI9VHGUPrkmPfVDcLg0VJV5JZkQGaoe_z3n5YAXFkPB03OBjo22Hd5dY-KVrqK5kLxA3cu1rgk-xgCdaky_Mgiux1jFqBqNr1bGV6OrFcvVyvhqzC6uZV8UuCnv9ToP0AsLA0HFxozWb03A_0K13txI2L9GaNCKBkc9gyXEq52pmCm6howMlq8II-DV_wG3aOAP0xZFYw |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1089_nat_2018_0739 crossref_primary_10_1007_s10557_022_07391_3 crossref_primary_10_1155_2020_2687692 crossref_primary_10_1021_acs_chemrev_7b00504 crossref_primary_10_1002_cpt_263 crossref_primary_10_1007_s10557_015_6588_3 crossref_primary_10_1161_CIRCRESAHA_114_304575 crossref_primary_10_1021_acs_accounts_9b00368 crossref_primary_10_1038_nrg3978 crossref_primary_10_1016_j_drudis_2022_04_015 crossref_primary_10_1111_jphp_13092 crossref_primary_10_1016_j_apsb_2020_01_015 crossref_primary_10_2217_clp_15_40 crossref_primary_10_1016_j_ymthe_2017_12_021 crossref_primary_10_1080_17425247_2025_2466767 crossref_primary_10_1007_s11883_015_0499_4 crossref_primary_10_1016_j_drudis_2019_04_007 crossref_primary_10_5551_jat_64454 crossref_primary_10_1080_14712598_2016_1196182 crossref_primary_10_1039_C8TB02484G crossref_primary_10_1038_s42255_020_0247_0 crossref_primary_10_2174_1389557518666180423111442 crossref_primary_10_1016_j_plipres_2017_09_001 crossref_primary_10_1172_JCI94585 crossref_primary_10_1136_bmjebm_2020_111448 crossref_primary_10_5339_gcsp_2014_30 crossref_primary_10_1158_1535_7163_MCT_15_0201_T crossref_primary_10_1016_j_bmcl_2018_10_029 crossref_primary_10_3390_pharmaceutics11080360 crossref_primary_10_1055_a_2287_2919 crossref_primary_10_1016_j_cjca_2016_04_013 crossref_primary_10_1016_j_atherosclerosis_2015_12_018 crossref_primary_10_3390_biomedicines10081918 crossref_primary_10_1161_JAHA_123_032031 crossref_primary_10_1080_15476286_2016_1208323 crossref_primary_10_1038_mt_2016_127 crossref_primary_10_7861_clinmedicine_16_4_353 crossref_primary_10_1155_2022_8129513 crossref_primary_10_1016_j_ecl_2022_02_004 crossref_primary_10_1007_s40265_016_0613_0 crossref_primary_10_1161_JAHA_114_001084 crossref_primary_10_1016_j_phrs_2017_04_008 crossref_primary_10_1016_j_addr_2020_07_022 crossref_primary_10_1007_s11883_023_01156_5 crossref_primary_10_1177_20420188211058323 crossref_primary_10_56095_eaj_v1i1_7 crossref_primary_10_1080_14740338_2019_1681395 crossref_primary_10_2174_1381612826666200922153045 crossref_primary_10_1186_s12944_022_01649_3 crossref_primary_10_3389_fgene_2014_00364 crossref_primary_10_1161_CIRCULATIONAHA_123_067957 crossref_primary_10_2745_dds_29_30 crossref_primary_10_1016_j_coph_2015_07_005 crossref_primary_10_1016_j_jacl_2016_07_004 crossref_primary_10_1016_j_jconrel_2018_07_026 crossref_primary_10_1016_j_cca_2014_07_008 crossref_primary_10_35693_2500_1388_2021_6_1_54_60 crossref_primary_10_3389_fbioe_2019_00489 crossref_primary_10_1002_wrna_1363 crossref_primary_10_1007_s11356_021_15623_6 crossref_primary_10_1038_ncomms8969 crossref_primary_10_1093_infdis_jiu828 crossref_primary_10_1016_j_jconrel_2015_07_014 crossref_primary_10_1021_acsbiomaterials_5b00203 crossref_primary_10_1016_j_mattod_2017_07_008 crossref_primary_10_1186_s13023_015_0326_6 crossref_primary_10_1007_s11427_018_9438_y crossref_primary_10_2217_clp_14_14 crossref_primary_10_5551_jat_RV17012 crossref_primary_10_1681_ASN_2016030338 crossref_primary_10_1016_j_ymthe_2021_06_002 crossref_primary_10_1038_s41598_019_46745_0 crossref_primary_10_3390_biomedicines9070793 crossref_primary_10_1007_s40265_022_01691_6 crossref_primary_10_1016_j_poly_2022_116124 crossref_primary_10_1186_s12916_015_0358_8 crossref_primary_10_1016_j_cjca_2016_12_019 crossref_primary_10_1016_j_antiviral_2015_06_019 crossref_primary_10_1096_fj_201701084RR crossref_primary_10_1080_00325481_2020_1751422 crossref_primary_10_3390_jcm10143185 crossref_primary_10_1016_j_jconrel_2016_08_002 crossref_primary_10_1160_TH14_06_0505 crossref_primary_10_1097_MED_0000000000000230 crossref_primary_10_1016_j_mayocp_2023_11_003 crossref_primary_10_1016_j_chembiol_2016_08_016 crossref_primary_10_1371_journal_pone_0090863 crossref_primary_10_1080_14656566_2020_1799978 crossref_primary_10_1016_j_addr_2020_06_026 crossref_primary_10_1038_clpt_2014_76 crossref_primary_10_1016_j_addr_2016_04_013 crossref_primary_10_1177_1074248414539562 crossref_primary_10_1093_eurheartj_ehv174 crossref_primary_10_1016_j_omtn_2016_12_003 crossref_primary_10_1021_jacs_5b09974 crossref_primary_10_1517_17425247_2016_1154531 crossref_primary_10_2147_IJN_S250872 crossref_primary_10_3389_fcvm_2018_00199 crossref_primary_10_1186_s12933_023_01752_4 crossref_primary_10_1152_ajpendo_00528_2014 crossref_primary_10_1016_j_omtm_2019_04_009 crossref_primary_10_1016_j_ccl_2017_12_006 crossref_primary_10_2174_1568026619666190809094203 crossref_primary_10_2217_fca_2018_0067 crossref_primary_10_3390_jcm10112467 crossref_primary_10_1016_j_metabol_2024_156064 crossref_primary_10_1016_j_biopha_2018_05_024 crossref_primary_10_1124_pr_120_019554 crossref_primary_10_1136_heartjnl_2016_310844 crossref_primary_10_1002_prp2_1080 crossref_primary_10_1016_j_phrs_2022_106439 crossref_primary_10_2174_1570161116666180209112351 crossref_primary_10_1016_j_jacl_2015_08_002 crossref_primary_10_1073_pnas_2207841119 crossref_primary_10_1002_smll_202103025 crossref_primary_10_1016_j_ejpb_2017_06_006 crossref_primary_10_1093_nar_gkw911 crossref_primary_10_1016_j_biopha_2021_112227 crossref_primary_10_1080_17425255_2018_1416094 crossref_primary_10_2174_1874467216666221202144813 crossref_primary_10_3390_ijms24044019 crossref_primary_10_1007_s12195_016_0436_9 crossref_primary_10_1097_MOL_0000000000000182 crossref_primary_10_1002_med_21718 crossref_primary_10_1016_j_ymthe_2021_11_007 crossref_primary_10_1080_13543784_2020_1708324 crossref_primary_10_1164_rccm_201505_0876CI crossref_primary_10_1007_s40256_018_0270_7 crossref_primary_10_3390_ijms222212109 crossref_primary_10_1016_j_actbio_2015_03_029 crossref_primary_10_1016_j_jacl_2014_10_002 crossref_primary_10_1016_j_abb_2016_03_008 crossref_primary_10_1517_17425247_2015_996545 crossref_primary_10_1016_j_jbiosc_2020_10_009 crossref_primary_10_1016_j_yrtph_2017_09_028 crossref_primary_10_1016_j_clinthera_2015_09_004 crossref_primary_10_1177_1074248414545127 crossref_primary_10_1517_14728214_2015_1035709 crossref_primary_10_1007_s00395_015_0463_z crossref_primary_10_3390_pharmaceutics14061252 crossref_primary_10_1002_anie_201708744 crossref_primary_10_1016_j_nantod_2022_101514 crossref_primary_10_1097_MED_0000000000000137 crossref_primary_10_1038_nature14299 crossref_primary_10_1016_j_cell_2021_12_021 crossref_primary_10_1016_j_omtn_2019_10_045 crossref_primary_10_1016_j_jff_2016_02_042 crossref_primary_10_1055_a_1199_8496 crossref_primary_10_1097_MOL_0000000000000281 crossref_primary_10_1177_1074248418774043 crossref_primary_10_1007_s40256_018_0312_1 crossref_primary_10_1200_JCO_2013_55_0376 crossref_primary_10_1016_j_jacbts_2016_03_012 crossref_primary_10_1111_febs_13742 crossref_primary_10_1007_s10557_021_07293_w crossref_primary_10_1016_j_ejpb_2017_07_014 crossref_primary_10_1007_s40005_017_0353_5 crossref_primary_10_3389_fcvm_2024_1415668 crossref_primary_10_1186_s12951_022_01279_y crossref_primary_10_1038_s10038_017_0347_1 crossref_primary_10_1080_14740338_2022_1988568 crossref_primary_10_1194_jlr_M092486 crossref_primary_10_1016_j_athplu_2024_11_003 crossref_primary_10_1371_journal_pone_0102053 crossref_primary_10_1038_nrg3763 crossref_primary_10_1016_j_jacl_2019_11_001 crossref_primary_10_1080_17425255_2021_2029402 crossref_primary_10_1161_JAHA_115_002497 crossref_primary_10_1002_ped4_12004 crossref_primary_10_1016_j_phrs_2019_104413 crossref_primary_10_1093_eurheartj_ehx165 crossref_primary_10_1093_hmg_ddv476 crossref_primary_10_1007_s10565_019_09488_2 crossref_primary_10_1007_s40259_019_00399_6 crossref_primary_10_15252_embr_201439585 crossref_primary_10_1056_NEJMoa1609243 crossref_primary_10_1161_ATVBAHA_114_304406 crossref_primary_10_1016_j_nano_2021_102480 crossref_primary_10_1055_a_1932_6448 crossref_primary_10_3892_etm_2015_2573 crossref_primary_10_3389_fphys_2018_00953 crossref_primary_10_1016_j_omtn_2018_02_003 crossref_primary_10_3389_fmicb_2024_1393646 crossref_primary_10_1016_j_jacc_2020_05_070 crossref_primary_10_1161_ATVBAHA_122_318354 crossref_primary_10_1016_j_cmet_2018_03_004 crossref_primary_10_1007_s40256_018_0303_2 crossref_primary_10_1016_j_jconrel_2015_10_024 crossref_primary_10_1016_j_cca_2024_119982 crossref_primary_10_1111_bcp_12738 crossref_primary_10_7759_cureus_16664 crossref_primary_10_1016_j_jconrel_2016_06_042 crossref_primary_10_1016_j_pharmthera_2014_07_004 crossref_primary_10_1007_s11886_016_0743_8 crossref_primary_10_1016_j_ejphar_2024_177110 crossref_primary_10_1038_aps_2016_134 crossref_primary_10_1016_j_jacc_2020_11_079 crossref_primary_10_15829_1560_4071_2022_5271 crossref_primary_10_1016_j_ymthe_2022_06_012 crossref_primary_10_1089_nat_2017_0715 crossref_primary_10_1016_j_addr_2020_03_001 crossref_primary_10_1124_jpet_114_214221 crossref_primary_10_1146_annurev_med_042716_091351 crossref_primary_10_1038_s41569_018_0073_1 crossref_primary_10_1172_JCI99417 crossref_primary_10_1016_j_clinthera_2015_08_001 crossref_primary_10_1016_j_metabol_2023_155774 crossref_primary_10_1161_JAHA_115_001937 crossref_primary_10_1517_17425247_2014_945421 crossref_primary_10_1016_j_ijpharm_2017_01_016 crossref_primary_10_1111_bph_15782 crossref_primary_10_1002_hep4_1405 crossref_primary_10_1042_CS20171300 crossref_primary_10_1016_j_ymthe_2022_11_014 crossref_primary_10_1161_ATVBAHA_118_311569 crossref_primary_10_1161_CIRCRESAHA_114_301621 crossref_primary_10_1007_s11883_014_0434_0 crossref_primary_10_1371_journal_pone_0162414 crossref_primary_10_1007_s11883_017_0684_8 crossref_primary_10_1016_j_bmc_2020_115344 crossref_primary_10_1146_annurev_pharmtox_011613_140025 crossref_primary_10_1016_S2213_8587_16_00074_7 crossref_primary_10_31083_j_rcm2311375 crossref_primary_10_3390_nu6125517 crossref_primary_10_1007_s10557_015_6602_9 crossref_primary_10_2174_0115734072270060230921093431 crossref_primary_10_17816_brmma321350 crossref_primary_10_1016_j_phrs_2024_107102 crossref_primary_10_15252_emmm_201506174 crossref_primary_10_1016_S0140_6736_14_61009_6 crossref_primary_10_17816_RCF19137_46 crossref_primary_10_1007_s11883_022_01056_0 crossref_primary_10_1016_j_plipres_2014_07_002 crossref_primary_10_1253_jjcsc_27_0_64 crossref_primary_10_1038_s41587_023_02105_y crossref_primary_10_1016_j_ijpharm_2016_06_124 crossref_primary_10_1097_CRD_0000000000000452 crossref_primary_10_1016_j_celrep_2014_02_046 crossref_primary_10_1002_jimd_12251 crossref_primary_10_1038_nm_3847 crossref_primary_10_1038_nbt_4182 crossref_primary_10_1097_MS9_0000000000000089 crossref_primary_10_1016_j_pharmthera_2020_107592 crossref_primary_10_1080_17512433_2020_1839417 crossref_primary_10_1007_s00395_017_0619_0 crossref_primary_10_1042_CS20160403 crossref_primary_10_1080_14728222_2022_2161887 crossref_primary_10_1016_j_ymeth_2021_06_004 crossref_primary_10_1016_j_omtn_2020_10_009 crossref_primary_10_1089_hum_2015_074 crossref_primary_10_1161_CIRCRESAHA_114_304800 crossref_primary_10_3390_diseases6030063 crossref_primary_10_1016_j_tcm_2015_01_009 crossref_primary_10_1097_CRD_0000000000000102 crossref_primary_10_1016_j_cmet_2016_01_005 crossref_primary_10_1111_bph_16409 crossref_primary_10_1016_j_jacc_2014_01_060 crossref_primary_10_1253_circj_CJ_16_0266 crossref_primary_10_1016_j_biotechadv_2019_04_012 crossref_primary_10_1080_13543784_2018_1442435 crossref_primary_10_1038_nn_4411 crossref_primary_10_1016_j_medcle_2015_04_002 crossref_primary_10_1093_nar_gkx632 crossref_primary_10_18632_aging_205347 crossref_primary_10_1016_j_jjcc_2022_02_009 crossref_primary_10_1038_s41573_021_00198_1 crossref_primary_10_1016_j_pharmthera_2025_108812 crossref_primary_10_1007_s00125_016_4178_y crossref_primary_10_1093_eurheartj_ehab841 crossref_primary_10_1136_heartjnl_2021_319629 crossref_primary_10_1007_s40256_024_00702_z crossref_primary_10_1016_S2213_8587_22_00353_9 crossref_primary_10_1080_07853890_2018_1457795 crossref_primary_10_1038_mt_2015_175 crossref_primary_10_1007_s40256_016_0179_y crossref_primary_10_1097_FJC_0000000000001053 crossref_primary_10_1016_j_ijcard_2016_11_177 crossref_primary_10_1016_j_arteri_2024_07_003 crossref_primary_10_1080_17512433_2017_1378096 crossref_primary_10_1002_jcp_27972 crossref_primary_10_1021_acsami_0c07559 crossref_primary_10_3390_molecules201017944 crossref_primary_10_3390_ph17030289 crossref_primary_10_30629_0023_2149_2020_98_11_12_739_744 crossref_primary_10_3390_biomedicines10050970 crossref_primary_10_1016_j_jconrel_2017_09_012 crossref_primary_10_3390_ijms26041743 crossref_primary_10_1002_ardp_202400492 crossref_primary_10_1016_j_atherosclerosis_2014_12_017 crossref_primary_10_1080_14712598_2017_1279602 crossref_primary_10_1016_j_cpcardiol_2024_102863 crossref_primary_10_1007_s11886_020_01427_6 crossref_primary_10_1111_febs_14654 crossref_primary_10_2174_0109298673262124231102042914 crossref_primary_10_1007_s12471_021_01600_8 crossref_primary_10_1089_nat_2017_0671 crossref_primary_10_1517_14712598_2015_984682 crossref_primary_10_1016_j_trsl_2019_07_006 crossref_primary_10_4330_wjc_v9_i2_76 crossref_primary_10_1038_nature_2013_13873 crossref_primary_10_1016_j_healun_2015_08_012 crossref_primary_10_3390_ijms24098062 crossref_primary_10_1186_s12915_018_0624_2 crossref_primary_10_1586_14779072_2014_954551 crossref_primary_10_1007_s00210_022_02245_z crossref_primary_10_1002_adma_202002932 crossref_primary_10_1080_14740338_2019_1620730 crossref_primary_10_1002_wnan_1416 crossref_primary_10_31083_j_fbl2810258 crossref_primary_10_1016_j_ejphar_2023_175721 crossref_primary_10_3390_ijms22169082 crossref_primary_10_1177_2047487319831500 crossref_primary_10_1016_j_hlc_2016_12_005 crossref_primary_10_1007_s00059_014_4083_4 crossref_primary_10_1097_MOL_0000000000000240 crossref_primary_10_1016_j_ejphar_2015_03_099 crossref_primary_10_1038_nrcardio_2014_84 crossref_primary_10_1016_j_medcli_2015_04_007 crossref_primary_10_1038_nbt_4136 crossref_primary_10_1021_jm5006594 crossref_primary_10_1124_pr_116_012989 crossref_primary_10_1016_j_jjcc_2017_07_002 crossref_primary_10_1016_j_pharmthera_2016_04_011 crossref_primary_10_1002_cpt_8 crossref_primary_10_1016_j_vph_2014_05_011 crossref_primary_10_3389_fimmu_2023_1126823 crossref_primary_10_1007_s00228_021_03149_2 crossref_primary_10_1016_j_drudis_2018_05_030 crossref_primary_10_1074_jbc_M114_594861 crossref_primary_10_3390_ijms25010328 crossref_primary_10_1002_wrna_1324 crossref_primary_10_3390_ijms22020660 crossref_primary_10_1016_j_addr_2015_01_007 crossref_primary_10_1038_nm0214_109 crossref_primary_10_3390_pharmaceutics14020398 crossref_primary_10_1089_dna_2020_6474 crossref_primary_10_1007_s12272_019_01141_0 crossref_primary_10_1007_s00059_016_4435_3 crossref_primary_10_3390_pharmaceutics13081200 crossref_primary_10_3390_molecules25051029 crossref_primary_10_1038_s41587_023_01758_z crossref_primary_10_1080_14712598_2017_1341485 crossref_primary_10_1177_2047487320916964 crossref_primary_10_1038_nnano_2014_155 crossref_primary_10_1007_s11883_014_0439_8 crossref_primary_10_1080_14779072_2023_2288169 crossref_primary_10_1038_nsmb_3471 crossref_primary_10_1002_jgm_3097 crossref_primary_10_3390_biomedicines12050961 crossref_primary_10_1038_s41392_020_0207_x crossref_primary_10_1016_j_phrs_2018_01_025 crossref_primary_10_1016_j_mehy_2015_11_010 crossref_primary_10_4155_tde_14_37 crossref_primary_10_1177_1087057116657312 crossref_primary_10_1016_j_jlr_2022_100293 crossref_primary_10_1038_nrd4685 crossref_primary_10_1021_acs_jmedchem_2c01290 crossref_primary_10_1016_j_atherosclerosis_2021_11_022 crossref_primary_10_1038_s41569_024_01094_y crossref_primary_10_1002_ange_201708744 crossref_primary_10_1016_j_ncrna_2023_06_002 crossref_primary_10_1016_j_adcanc_2023_100103 crossref_primary_10_1002_jcla_24552 crossref_primary_10_1038_s41467_022_33061_x crossref_primary_10_1038_mtna_2016_68 crossref_primary_10_12688_f1000research_8459_1 crossref_primary_10_1016_j_jacl_2015_01_001 crossref_primary_10_1039_D0BM00196A crossref_primary_10_1016_j_omtn_2017_04_003 crossref_primary_10_1080_17425255_2020_1749261 crossref_primary_10_2217_fca_2020_0216 crossref_primary_10_1097_MOL_0000000000000954 crossref_primary_10_3389_fphar_2024_1353848 crossref_primary_10_1517_14712598_2015_1084282 crossref_primary_10_1016_j_cjca_2016_09_010 crossref_primary_10_4155_tde_13_138 crossref_primary_10_1146_annurev_pharmtox_010715_103633 crossref_primary_10_18632_oncoscience_103 crossref_primary_10_1007_s00383_021_05009_7 crossref_primary_10_1007_s11886_015_0659_8 crossref_primary_10_1080_17460441_2020_1704728 crossref_primary_10_1126_scitranslmed_abe9117 crossref_primary_10_1097_MOL_0000000000000549 crossref_primary_10_1146_annurev_med_051215_030943 crossref_primary_10_1016_j_vph_2014_12_002 crossref_primary_10_1038_mtna_2015_36 crossref_primary_10_1038_mtna_2014_61 crossref_primary_10_1002_mc_23260 crossref_primary_10_1016_j_ophtha_2017_03_042 crossref_primary_10_5339_gcsp_2015_59 crossref_primary_10_7861_clinmedicine_14_6_s41 crossref_primary_10_3390_v14092052 crossref_primary_10_1073_pnas_1406228111 crossref_primary_10_1186_s12933_022_01542_4 crossref_primary_10_1080_08916934_2022_2051142 crossref_primary_10_1016_j_mcna_2024_03_005 crossref_primary_10_1016_j_pcad_2016_07_006 crossref_primary_10_1016_j_addr_2024_115302 crossref_primary_10_1161_CIRCRESAHA_115_304008 crossref_primary_10_4049_jimmunol_1402989 crossref_primary_10_1080_13543776_2016_1206080 crossref_primary_10_1186_s12916_015_0503_4 crossref_primary_10_12677_ACM_2023_1381874 crossref_primary_10_1016_j_clinthera_2023_07_008 crossref_primary_10_1038_mtna_2015_23 crossref_primary_10_1080_14756366_2017_1335310 crossref_primary_10_3109_13506129_2016_1160882 crossref_primary_10_1007_s11883_015_0487_8 crossref_primary_10_7831_ras_7_10 crossref_primary_10_1158_1940_6207_CAPR_14_0079 crossref_primary_10_1016_j_numecd_2024_10_017 crossref_primary_10_3390_genes8050135 crossref_primary_10_1021_mp500400k crossref_primary_10_1016_j_jaci_2015_12_1344 crossref_primary_10_1021_acs_jmedchem_8b00650 crossref_primary_10_1016_j_omtn_2020_01_018 crossref_primary_10_4155_tde_14_23 crossref_primary_10_1002_cbic_201500023 crossref_primary_10_3389_fmmed_2023_1140997 crossref_primary_10_1016_j_ekir_2017_03_016 crossref_primary_10_1097_MOL_0000000000000877 crossref_primary_10_1038_mtna_2014_71 crossref_primary_10_1016_j_ecl_2014_08_008 crossref_primary_10_1016_j_amjcard_2020_08_018 crossref_primary_10_1146_annurev_pharmtox_010716_104944 crossref_primary_10_1194_jlr_M053207 crossref_primary_10_12677_ACM_2022_1281061 crossref_primary_10_1016_j_artere_2025_100730 |
| Cites_doi | 10.1016/j.jacc.2012.08.986 10.1016/j.jacl.2012.05.004 10.1038/ng1161 10.1016/j.tibs.2006.12.008 10.1016/S0828-282X(09)70715-9 10.1056/NEJMc1204929 10.1038/nature02873 10.1016/S0002-9149(03)00474-0 10.1073/pnas.0805434105 10.1016/j.amjcard.2005.04.019 10.1016/j.atherosclerosis.2010.05.027 10.1194/jlr.R800091-JLR200 10.1073/pnas.0501652102 10.1016/S0140-6736(05)67394-1 10.1016/j.jacl.2010.01.007 10.1086/507488 10.1016/S0140-6736(08)60104-X 10.1016/j.addr.2012.06.007 10.1001/jama.2012.25790 10.1194/jlr.M700437-JLR200 10.1210/jc.2009-0141 10.1016/j.atherosclerosis.2006.08.039 10.1056/NEJMoa1201832 10.1186/1758-907X-1-14 10.1016/j.jacc.2004.07.001 10.1161/CIRCULATIONAHA.112.144055 10.1056/NEJMoa054013 10.1056/NEJMoa1105803 10.1517/14712598.2012.748743 10.1158/2159-8290.CD-12-0429 10.1016/j.clinthera.2009.02.017 10.1002/anie.201203263 10.1038/35888 10.2165/11539550-000000000-00000 10.1194/jlr.M008144 10.1074/jbc.M109.037085 |
| ContentType | Journal Article |
| Copyright | 2014 Elsevier Ltd Elsevier Ltd 2015 INIST-CNRS Copyright © 2014 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jan 4, 2014 |
| Copyright_xml | – notice: 2014 Elsevier Ltd – notice: Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2014 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jan 4, 2014 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7X8 7TM 7U1 8FD FR3 P64 RC3 5PM |
| DOI | 10.1016/S0140-6736(13)61914-5 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland British Nursing Database (Proquest) British Nursing Index ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial MEDLINE - Academic Nucleic Acids Abstracts Risk Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) MEDLINE - Academic Risk Abstracts Nucleic Acids Abstracts Genetics Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts |
| DatabaseTitleList | MEDLINE Risk Abstracts MEDLINE - Academic ProQuest One Psychology Risk Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 68 |
| ExternalDocumentID | PMC4387547 3172139901 24094767 28036945 10_1016_S0140_6736_13_61914_5 S0140673613619145 1_s2_0_S0140673613619145 |
| Genre | Multicenter Study Clinical Trial, Phase I Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation | Alnylam Pharmaceuticals. |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: P01 HL020948 – fundername: NHLBI NIH HHS grantid: HL020948 |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUWG ACGFS ACGOD ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGCQF AGHFR AHHHB AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M41 M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ PUEGO R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU YYM Z5R ZMT .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 AAYXX ADXHL AGQPQ AGRNS AIGII CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7TM 7U1 8FD FR3 P64 RC3 5PM |
| ID | FETCH-LOGICAL-c653t-ba5d1b568386984f5d9f042f01fb4df32ab9bb96938469e88b51f950db06e05b3 |
| IEDL.DBID | 7X7 |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Thu Aug 21 18:18:15 EDT 2025 Thu Jul 10 19:12:28 EDT 2025 Fri Jul 11 04:09:52 EDT 2025 Tue Aug 05 10:46:42 EDT 2025 Sat Aug 23 13:33:59 EDT 2025 Mon Jul 21 06:04:27 EDT 2025 Wed Apr 02 08:10:23 EDT 2025 Tue Jul 01 03:16:14 EDT 2025 Thu Apr 24 23:00:39 EDT 2025 Fri Feb 23 02:30:17 EST 2024 Sun Feb 23 10:19:20 EST 2025 Tue Aug 26 18:33:14 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9911 |
| Keywords | Drug RNA interference Serine endopeptidases Healthy subject Enzyme Cholesterol LDL Subtilisin Concentration Medicine Peptidases Gene silencing Randomization Kexin RNA synthesis Placebo Phase I trial Hydrolases Clinical trial Serum |
| Language | English |
| License | CC BY 4.0 Copyright © 2014 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c653t-ba5d1b568386984f5d9f042f01fb4df32ab9bb96938469e88b51f950db06e05b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 24094767 |
| PQID | 1473891662 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4387547 proquest_miscellaneous_1505327150 proquest_miscellaneous_1492652966 proquest_miscellaneous_1490714784 proquest_journals_1473891662 pubmed_primary_24094767 pascalfrancis_primary_28036945 crossref_citationtrail_10_1016_S0140_6736_13_61914_5 crossref_primary_10_1016_S0140_6736_13_61914_5 elsevier_sciencedirect_doi_10_1016_S0140_6736_13_61914_5 elsevier_clinicalkeyesjournals_1_s2_0_S0140673613619145 elsevier_clinicalkey_doi_10_1016_S0140_6736_13_61914_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-01-04 |
| PublicationDateYYYYMMDD | 2014-01-04 |
| PublicationDate_xml | – month: 01 year: 2014 text: 2014-01-04 day: 04 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2014 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | Davignon, Dubuc (bib20) 2009; 120 Milazzo, Antinori (bib29) 2012; 366 Stein, Mellis, Yancopoulos (bib23) 2012; 366 Adams, Tsang, Wright (bib38) 2012; 12 Cohen, Boerwinkle, Mosley, Hobbs (bib14) 2006; 354 Sullivan, Olsson, Scott (bib26) 2012; 308 Frank-Kamenetsky, Grefhorst, Anderson (bib33) 2008; 105 Genest, McPherson, Frohlich (bib8) 2009; 25 Meister, Tuschl (bib31) 2004; 431 Davidson, Maki, Pearson (bib4) 2005; 96 Dias, Shaywitz, Wasserman (bib24) 2012; 60 Careskey, Davis, Alborn, Troutt, Cao, Konrad (bib19) 2008; 49 Abifadel, Varret, Rabes (bib11) 2003; 34 Foody, Sajjan, Hu (bib9) 2010; 4 Roth, McKenney, Hanotin, Asset, Stein (bib27) 2012; 367 Sniderman, Thanassoulis, Couture, Williams, Alam, Furberg (bib3) 2012; 6 (bib6) 2005; 366 Grundy, Cleeman, Merz (bib1) 2004; 44 Rashid, Curtis, Garuti (bib18) 2005; 102 (bib7) 2008; 371 Thomas, Tershakovec, Jones-Burton, Sayeed, Foody (bib10) 2010; 27 Foley, Simpson, Crouse, Weiss, Markson, Alexander (bib5) 2003; 92 Costet, Hoffmann, Cariou (bib21) 2010; 212 Barros, Gollob (bib36) 2012; 64 Lakoski, Lagace, Cohen, Horton, Hobbs (bib37) 2009; 94 Horton, Cohen, Hobbs (bib12) 2007; 32 Jayaraman, Ansell, Mui (bib34) 2012; 51 Zhao, Tuakli-Wosornu, Lagace (bib16) 2006; 79 Fire, Xu, Montgomery, Kostas, Driver, Mello (bib39) 1998; 391 Vaishnaw, Gollob, Gamba-Vitalo (bib32) 2010; 1 Banerjee, Shah, Al-Rasadi (bib28) 2012; 366 Welder, Zineh, Pacanowski, Troutt, Cao, Konrad (bib22) 2010; 51 Horton, Cohen, Hobbs (bib15) 2009; 50 Delahoy, Magliano, Webb, Grobler, Liew (bib2) 2009; 31 Raal, Scott, Somaratne (bib25) 2012; 126 Hooper, Burnett (bib30) 2013; 13 Hooper, Marais, Tanyanyiwa, Burnett (bib17) 2007; 193 Poirier, Mayer, Poupon (bib13) 2009; 284 Tabernero, Shapiro, LoRusso (bib35) 2013; 3 Poirier (10.1016/S0140-6736(13)61914-5_bib13) 2009; 284 Lakoski (10.1016/S0140-6736(13)61914-5_bib37) 2009; 94 Careskey (10.1016/S0140-6736(13)61914-5_bib19) 2008; 49 Costet (10.1016/S0140-6736(13)61914-5_bib21) 2010; 212 Sullivan (10.1016/S0140-6736(13)61914-5_bib26) 2012; 308 Hooper (10.1016/S0140-6736(13)61914-5_bib30) 2013; 13 Horton (10.1016/S0140-6736(13)61914-5_bib12) 2007; 32 Grundy (10.1016/S0140-6736(13)61914-5_bib1) 2004; 44 Hooper (10.1016/S0140-6736(13)61914-5_bib17) 2007; 193 Foody (10.1016/S0140-6736(13)61914-5_bib9) 2010; 4 Banerjee (10.1016/S0140-6736(13)61914-5_bib28) 2012; 366 Barros (10.1016/S0140-6736(13)61914-5_bib36) 2012; 64 Adams (10.1016/S0140-6736(13)61914-5_bib38) 2012; 12 Jayaraman (10.1016/S0140-6736(13)61914-5_bib34) 2012; 51 Cohen (10.1016/S0140-6736(13)61914-5_bib14) 2006; 354 Foley (10.1016/S0140-6736(13)61914-5_bib5) 2003; 92 Delahoy (10.1016/S0140-6736(13)61914-5_bib2) 2009; 31 Zhao (10.1016/S0140-6736(13)61914-5_bib16) 2006; 79 Stein (10.1016/S0140-6736(13)61914-5_bib23) 2012; 366 Welder (10.1016/S0140-6736(13)61914-5_bib22) 2010; 51 Milazzo (10.1016/S0140-6736(13)61914-5_bib29) 2012; 366 Tabernero (10.1016/S0140-6736(13)61914-5_bib35) 2013; 3 Frank-Kamenetsky (10.1016/S0140-6736(13)61914-5_bib33) 2008; 105 Thomas (10.1016/S0140-6736(13)61914-5_bib10) 2010; 27 Meister (10.1016/S0140-6736(13)61914-5_bib31) 2004; 431 Fire (10.1016/S0140-6736(13)61914-5_bib39) 1998; 391 (10.1016/S0140-6736(13)61914-5_bib6) 2005; 366 Davignon (10.1016/S0140-6736(13)61914-5_bib20) 2009; 120 Rashid (10.1016/S0140-6736(13)61914-5_bib18) 2005; 102 Davidson (10.1016/S0140-6736(13)61914-5_bib4) 2005; 96 (10.1016/S0140-6736(13)61914-5_bib7) 2008; 371 Vaishnaw (10.1016/S0140-6736(13)61914-5_bib32) 2010; 1 Dias (10.1016/S0140-6736(13)61914-5_bib24) 2012; 60 Abifadel (10.1016/S0140-6736(13)61914-5_bib11) 2003; 34 Sniderman (10.1016/S0140-6736(13)61914-5_bib3) 2012; 6 Raal (10.1016/S0140-6736(13)61914-5_bib25) 2012; 126 Horton (10.1016/S0140-6736(13)61914-5_bib15) 2009; 50 Genest (10.1016/S0140-6736(13)61914-5_bib8) 2009; 25 Roth (10.1016/S0140-6736(13)61914-5_bib27) 2012; 367 18695239 - Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11915-20 16214597 - Lancet. 2005 Oct 8;366(9493):1267-78 12842255 - Am J Cardiol. 2003 Jul 1;92(1):79-81 20619837 - Atherosclerosis. 2010 Sep;212(1):246-51 19812802 - Can J Cardiol. 2009 Oct;25(10):567-79 16554528 - N Engl J Med. 2006 Mar 23;354(12):1264-72 23358650 - Cancer Discov. 2013 Apr;3(4):406-17 17215125 - Trends Biochem Sci. 2007 Feb;32(2):71-7 22435370 - N Engl J Med. 2012 Mar 22;366(12):1108-18 19020338 - J Lipid Res. 2009 Apr;50 Suppl:S172-7 23240807 - Expert Opin Biol Ther. 2013 Mar;13(3):429-35 22716984 - N Engl J Med. 2012 Jun 21;366(25):2425-6; author reply 2426 19302897 - Clin Ther. 2009 Feb;31(2):236-44 22732527 - Adv Drug Deliv Rev. 2012 Dec;64(15):1730-7 9486653 - Nature. 1998 Feb 19;391(6669):806-11 18033751 - J Lipid Res. 2008 Feb;49(2):394-8 22782619 - Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8529-33 23128163 - JAMA. 2012 Dec 19;308(23):2497-506 20525997 - J Lipid Res. 2010 Sep;51(9):2714-21 21087066 - Drugs Aging. 2010 Dec 1;27(12):959-72 19768174 - Trans Am Clin Climatol Assoc. 2009;120:163-73 23129602 - Circulation. 2012 Nov 13;126(20):2408-17 23235655 - Cochrane Database Syst Rev. 2012;12:CD008226 16909389 - Am J Hum Genet. 2006 Sep;79(3):514-23 15805190 - Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5374-9 19635789 - J Biol Chem. 2009 Oct 16;284(42):28856-64 22716983 - N Engl J Med. 2012 Jun 21;366(25):2425; author reply 2426 23083772 - J Am Coll Cardiol. 2012 Nov 6;60(19):1888-98 20615220 - Silence. 2010 Jul 08;1(1):14 16989838 - Atherosclerosis. 2007 Aug;193(2):445-8 22836065 - J Clin Lipidol. 2012 Jul-Aug;6(4):303-9 15372041 - Nature. 2004 Sep 16;431(7006):343-9 12730697 - Nat Genet. 2003 Jun;34(2):154-6 21122640 - J Clin Lipidol. 2010 Mar-Apr;4(2):126-32 18191683 - Lancet. 2008 Jan 12;371(9607):117-25 24145894 - Nat Rev Cardiol. 2013 Dec;10(12):682 23113833 - N Engl J Med. 2012 Nov 15;367(20):1891-900 16098311 - Am J Cardiol. 2005 Aug 15;96(4):556-63 19351729 - J Clin Endocrinol Metab. 2009 Jul;94(7):2537-43 24094769 - Lancet. 2014 Jan 4;383(9911):10-2 15358046 - J Am Coll Cardiol. 2004 Aug 4;44(3):720-32 |
| References_xml | – volume: 64 start-page: 1730 year: 2012 end-page: 1737 ident: bib36 article-title: Safety profile of RNAi nanomedicines publication-title: Adv Drug Deliv Rev – volume: 366 start-page: 2425 year: 2012 ident: bib29 article-title: Effect of a monoclonal antibody to PCSK9 on LDL cholesterol publication-title: N Engl J Med – volume: 120 start-page: 163 year: 2009 end-page: 173 ident: bib20 article-title: Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels publication-title: Trans Am Clin Climatol Assoc – volume: 212 start-page: 246 year: 2010 end-page: 251 ident: bib21 article-title: Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients publication-title: Atherosclerosis – volume: 367 start-page: 1891 year: 2012 end-page: 1900 ident: bib27 article-title: Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia publication-title: N Engl J Med – volume: 51 start-page: 2714 year: 2010 end-page: 2721 ident: bib22 article-title: High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol publication-title: J Lipid Res – volume: 4 start-page: 126 year: 2010 end-page: 132 ident: bib9 article-title: Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients publication-title: J Clin Lipidol – volume: 193 start-page: 445 year: 2007 end-page: 448 ident: bib17 article-title: The C679X mutation in publication-title: Atherosclerosis – volume: 1 start-page: 14 year: 2010 ident: bib32 article-title: A status report on RNAi therapeutics publication-title: Silence – volume: 284 start-page: 28856 year: 2009 end-page: 28864 ident: bib13 article-title: Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route publication-title: J Biol Chem – volume: 44 start-page: 720 year: 2004 end-page: 732 ident: bib1 article-title: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines publication-title: J Am Coll Cardiol – volume: 79 start-page: 514 year: 2006 end-page: 523 ident: bib16 article-title: Molecular characterization of loss-of-function mutations in publication-title: Am J Hum Genet – volume: 391 start-page: 806 year: 1998 end-page: 811 ident: bib39 article-title: Potent and specific genetic interference by double-stranded RNA in publication-title: Nature – volume: 366 start-page: 1108 year: 2012 end-page: 1118 ident: bib23 article-title: Effect of a monoclonal antibody to PCSK9 on LDL cholesterol publication-title: N Engl J Med – volume: 27 start-page: 959 year: 2010 end-page: 972 ident: bib10 article-title: Lipid lowering for secondary prevention of cardiovascular disease in older adults publication-title: Drugs Aging – volume: 366 start-page: 2425 year: 2012 end-page: 2426 ident: bib28 article-title: Effect of a monoclonal antibody to PCSK9 on LDL cholesterol publication-title: N Engl J Med – volume: 96 start-page: 556 year: 2005 end-page: 563 ident: bib4 article-title: Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations publication-title: Am J Cardiol – volume: 32 start-page: 71 year: 2007 end-page: 77 ident: bib12 article-title: Molecular biology of publication-title: Trends Biochem Sci – volume: 354 start-page: 1264 year: 2006 end-page: 1272 ident: bib14 article-title: Sequence variations in publication-title: N Engl J Med – volume: 12 year: 2012 ident: bib38 article-title: Lipid lowering efficacy of atorvastatin publication-title: Cochrane Database Syst Rev – volume: 366 start-page: 1267 year: 2005 end-page: 1278 ident: bib6 article-title: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins publication-title: Lancet – volume: 25 start-page: 567 year: 2009 end-page: 579 ident: bib8 article-title: 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations publication-title: Can J Cardiol – volume: 94 start-page: 2537 year: 2009 end-page: 2543 ident: bib37 article-title: Genetic and metabolic determinants of plasma PCSK9 levels publication-title: J Clin Endocrinol Metab – volume: 371 start-page: 117 year: 2008 end-page: 125 ident: bib7 article-title: Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis publication-title: Lancet – volume: 34 start-page: 154 year: 2003 end-page: 156 ident: bib11 article-title: Mutations in publication-title: Nat Genet – volume: 49 start-page: 394 year: 2008 end-page: 398 ident: bib19 article-title: Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 publication-title: J Lipid Res – volume: 60 start-page: 1888 year: 2012 end-page: 1898 ident: bib24 article-title: Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins publication-title: J Am Coll Cardiol – volume: 92 start-page: 79 year: 2003 end-page: 81 ident: bib5 article-title: Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events publication-title: Am J Cardiol – volume: 3 start-page: 406 year: 2013 end-page: 417 ident: bib35 article-title: First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement publication-title: Cancer Discov – volume: 31 start-page: 236 year: 2009 end-page: 244 ident: bib2 article-title: The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis publication-title: Clin Ther – volume: 6 start-page: 303 year: 2012 end-page: 309 ident: bib3 article-title: Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering publication-title: J Clin Lipidol – volume: 13 start-page: 429 year: 2013 end-page: 435 ident: bib30 article-title: Anti-PCSK9 therapies for the treatment of hypercholesterolemia publication-title: Expert Opin Biol Ther – volume: 102 start-page: 5374 year: 2005 end-page: 5379 ident: bib18 article-title: Decreased plasma cholesterol and hypersensitivity to statins in mice lacking publication-title: Proc Natl Acad Sci USA – volume: 105 start-page: 11915 year: 2008 end-page: 11920 ident: bib33 article-title: Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates publication-title: Proc Natl Acad Sci USA – volume: 50 start-page: S172 year: 2009 end-page: S177 ident: bib15 article-title: PCSK9: a convertase that coordinates LDL catabolism publication-title: J Lipid Res – volume: 308 start-page: 2497 year: 2012 end-page: 2506 ident: bib26 article-title: Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial publication-title: JAMA – volume: 51 start-page: 8529 year: 2012 end-page: 8533 ident: bib34 article-title: Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo publication-title: Angew Chem Int Ed Engl – volume: 126 start-page: 2408 year: 2012 end-page: 2417 ident: bib25 article-title: Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial publication-title: Circulation – volume: 431 start-page: 343 year: 2004 end-page: 349 ident: bib31 article-title: Mechanisms of gene silencing by double-stranded RNA publication-title: Nature – volume: 60 start-page: 1888 year: 2012 ident: 10.1016/S0140-6736(13)61914-5_bib24 article-title: Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2012.08.986 – volume: 6 start-page: 303 year: 2012 ident: 10.1016/S0140-6736(13)61914-5_bib3 article-title: Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering publication-title: J Clin Lipidol doi: 10.1016/j.jacl.2012.05.004 – volume: 34 start-page: 154 year: 2003 ident: 10.1016/S0140-6736(13)61914-5_bib11 article-title: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia publication-title: Nat Genet doi: 10.1038/ng1161 – volume: 32 start-page: 71 year: 2007 ident: 10.1016/S0140-6736(13)61914-5_bib12 article-title: Molecular biology of PCSK9: its role in LDL metabolism publication-title: Trends Biochem Sci doi: 10.1016/j.tibs.2006.12.008 – volume: 25 start-page: 567 year: 2009 ident: 10.1016/S0140-6736(13)61914-5_bib8 article-title: 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations publication-title: Can J Cardiol doi: 10.1016/S0828-282X(09)70715-9 – volume: 366 start-page: 2425 year: 2012 ident: 10.1016/S0140-6736(13)61914-5_bib29 article-title: Effect of a monoclonal antibody to PCSK9 on LDL cholesterol publication-title: N Engl J Med doi: 10.1056/NEJMc1204929 – volume: 431 start-page: 343 year: 2004 ident: 10.1016/S0140-6736(13)61914-5_bib31 article-title: Mechanisms of gene silencing by double-stranded RNA publication-title: Nature doi: 10.1038/nature02873 – volume: 92 start-page: 79 year: 2003 ident: 10.1016/S0140-6736(13)61914-5_bib5 article-title: Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events publication-title: Am J Cardiol doi: 10.1016/S0002-9149(03)00474-0 – volume: 105 start-page: 11915 year: 2008 ident: 10.1016/S0140-6736(13)61914-5_bib33 article-title: Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0805434105 – volume: 96 start-page: 556 year: 2005 ident: 10.1016/S0140-6736(13)61914-5_bib4 article-title: Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2005.04.019 – volume: 212 start-page: 246 year: 2010 ident: 10.1016/S0140-6736(13)61914-5_bib21 article-title: Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2010.05.027 – volume: 50 start-page: S172 issue: suppl year: 2009 ident: 10.1016/S0140-6736(13)61914-5_bib15 article-title: PCSK9: a convertase that coordinates LDL catabolism publication-title: J Lipid Res doi: 10.1194/jlr.R800091-JLR200 – volume: 102 start-page: 5374 year: 2005 ident: 10.1016/S0140-6736(13)61914-5_bib18 article-title: Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0501652102 – volume: 366 start-page: 1267 year: 2005 ident: 10.1016/S0140-6736(13)61914-5_bib6 article-title: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins publication-title: Lancet doi: 10.1016/S0140-6736(05)67394-1 – volume: 4 start-page: 126 year: 2010 ident: 10.1016/S0140-6736(13)61914-5_bib9 article-title: Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients publication-title: J Clin Lipidol doi: 10.1016/j.jacl.2010.01.007 – volume: 79 start-page: 514 year: 2006 ident: 10.1016/S0140-6736(13)61914-5_bib16 article-title: Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote publication-title: Am J Hum Genet doi: 10.1086/507488 – volume: 371 start-page: 117 year: 2008 ident: 10.1016/S0140-6736(13)61914-5_bib7 article-title: Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(08)60104-X – volume: 64 start-page: 1730 year: 2012 ident: 10.1016/S0140-6736(13)61914-5_bib36 article-title: Safety profile of RNAi nanomedicines publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2012.06.007 – volume: 308 start-page: 2497 year: 2012 ident: 10.1016/S0140-6736(13)61914-5_bib26 article-title: Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial publication-title: JAMA doi: 10.1001/jama.2012.25790 – volume: 49 start-page: 394 year: 2008 ident: 10.1016/S0140-6736(13)61914-5_bib19 article-title: Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 publication-title: J Lipid Res doi: 10.1194/jlr.M700437-JLR200 – volume: 120 start-page: 163 year: 2009 ident: 10.1016/S0140-6736(13)61914-5_bib20 article-title: Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels publication-title: Trans Am Clin Climatol Assoc – volume: 94 start-page: 2537 year: 2009 ident: 10.1016/S0140-6736(13)61914-5_bib37 article-title: Genetic and metabolic determinants of plasma PCSK9 levels publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2009-0141 – volume: 193 start-page: 445 year: 2007 ident: 10.1016/S0140-6736(13)61914-5_bib17 article-title: The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2006.08.039 – volume: 367 start-page: 1891 year: 2012 ident: 10.1016/S0140-6736(13)61914-5_bib27 article-title: Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1201832 – volume: 1 start-page: 14 year: 2010 ident: 10.1016/S0140-6736(13)61914-5_bib32 article-title: A status report on RNAi therapeutics publication-title: Silence doi: 10.1186/1758-907X-1-14 – volume: 12 year: 2012 ident: 10.1016/S0140-6736(13)61914-5_bib38 article-title: Lipid lowering efficacy of atorvastatin publication-title: Cochrane Database Syst Rev – volume: 44 start-page: 720 year: 2004 ident: 10.1016/S0140-6736(13)61914-5_bib1 article-title: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2004.07.001 – volume: 126 start-page: 2408 year: 2012 ident: 10.1016/S0140-6736(13)61914-5_bib25 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.112.144055 – volume: 354 start-page: 1264 year: 2006 ident: 10.1016/S0140-6736(13)61914-5_bib14 article-title: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease publication-title: N Engl J Med doi: 10.1056/NEJMoa054013 – volume: 366 start-page: 1108 year: 2012 ident: 10.1016/S0140-6736(13)61914-5_bib23 article-title: Effect of a monoclonal antibody to PCSK9 on LDL cholesterol publication-title: N Engl J Med doi: 10.1056/NEJMoa1105803 – volume: 13 start-page: 429 year: 2013 ident: 10.1016/S0140-6736(13)61914-5_bib30 article-title: Anti-PCSK9 therapies for the treatment of hypercholesterolemia publication-title: Expert Opin Biol Ther doi: 10.1517/14712598.2012.748743 – volume: 3 start-page: 406 year: 2013 ident: 10.1016/S0140-6736(13)61914-5_bib35 article-title: First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-12-0429 – volume: 31 start-page: 236 year: 2009 ident: 10.1016/S0140-6736(13)61914-5_bib2 article-title: The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis publication-title: Clin Ther doi: 10.1016/j.clinthera.2009.02.017 – volume: 51 start-page: 8529 year: 2012 ident: 10.1016/S0140-6736(13)61914-5_bib34 article-title: Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo publication-title: Angew Chem Int Ed Engl doi: 10.1002/anie.201203263 – volume: 391 start-page: 806 year: 1998 ident: 10.1016/S0140-6736(13)61914-5_bib39 article-title: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans publication-title: Nature doi: 10.1038/35888 – volume: 27 start-page: 959 year: 2010 ident: 10.1016/S0140-6736(13)61914-5_bib10 article-title: Lipid lowering for secondary prevention of cardiovascular disease in older adults publication-title: Drugs Aging doi: 10.2165/11539550-000000000-00000 – volume: 51 start-page: 2714 year: 2010 ident: 10.1016/S0140-6736(13)61914-5_bib22 article-title: High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol publication-title: J Lipid Res doi: 10.1194/jlr.M008144 – volume: 284 start-page: 28856 year: 2009 ident: 10.1016/S0140-6736(13)61914-5_bib13 article-title: Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route publication-title: J Biol Chem doi: 10.1074/jbc.M109.037085 – volume: 366 start-page: 2425 year: 2012 ident: 10.1016/S0140-6736(13)61914-5_bib28 article-title: Effect of a monoclonal antibody to PCSK9 on LDL cholesterol publication-title: N Engl J Med doi: 10.1056/NEJMc1204929 – reference: 16214597 - Lancet. 2005 Oct 8;366(9493):1267-78 – reference: 23129602 - Circulation. 2012 Nov 13;126(20):2408-17 – reference: 21122640 - J Clin Lipidol. 2010 Mar-Apr;4(2):126-32 – reference: 24094769 - Lancet. 2014 Jan 4;383(9911):10-2 – reference: 22836065 - J Clin Lipidol. 2012 Jul-Aug;6(4):303-9 – reference: 23240807 - Expert Opin Biol Ther. 2013 Mar;13(3):429-35 – reference: 19812802 - Can J Cardiol. 2009 Oct;25(10):567-79 – reference: 20525997 - J Lipid Res. 2010 Sep;51(9):2714-21 – reference: 19635789 - J Biol Chem. 2009 Oct 16;284(42):28856-64 – reference: 16098311 - Am J Cardiol. 2005 Aug 15;96(4):556-63 – reference: 23113833 - N Engl J Med. 2012 Nov 15;367(20):1891-900 – reference: 9486653 - Nature. 1998 Feb 19;391(6669):806-11 – reference: 18033751 - J Lipid Res. 2008 Feb;49(2):394-8 – reference: 23083772 - J Am Coll Cardiol. 2012 Nov 6;60(19):1888-98 – reference: 21087066 - Drugs Aging. 2010 Dec 1;27(12):959-72 – reference: 15358046 - J Am Coll Cardiol. 2004 Aug 4;44(3):720-32 – reference: 18191683 - Lancet. 2008 Jan 12;371(9607):117-25 – reference: 19302897 - Clin Ther. 2009 Feb;31(2):236-44 – reference: 22716984 - N Engl J Med. 2012 Jun 21;366(25):2425-6; author reply 2426 – reference: 20615220 - Silence. 2010 Jul 08;1(1):14 – reference: 22782619 - Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8529-33 – reference: 22732527 - Adv Drug Deliv Rev. 2012 Dec;64(15):1730-7 – reference: 16909389 - Am J Hum Genet. 2006 Sep;79(3):514-23 – reference: 22435370 - N Engl J Med. 2012 Mar 22;366(12):1108-18 – reference: 19351729 - J Clin Endocrinol Metab. 2009 Jul;94(7):2537-43 – reference: 15372041 - Nature. 2004 Sep 16;431(7006):343-9 – reference: 23358650 - Cancer Discov. 2013 Apr;3(4):406-17 – reference: 20619837 - Atherosclerosis. 2010 Sep;212(1):246-51 – reference: 24145894 - Nat Rev Cardiol. 2013 Dec;10(12):682 – reference: 19768174 - Trans Am Clin Climatol Assoc. 2009;120:163-73 – reference: 12730697 - Nat Genet. 2003 Jun;34(2):154-6 – reference: 18695239 - Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11915-20 – reference: 23128163 - JAMA. 2012 Dec 19;308(23):2497-506 – reference: 16989838 - Atherosclerosis. 2007 Aug;193(2):445-8 – reference: 17215125 - Trends Biochem Sci. 2007 Feb;32(2):71-7 – reference: 15805190 - Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5374-9 – reference: 16554528 - N Engl J Med. 2006 Mar 23;354(12):1264-72 – reference: 23235655 - Cochrane Database Syst Rev. 2012;12:CD008226 – reference: 12842255 - Am J Cardiol. 2003 Jul 1;92(1):79-81 – reference: 19020338 - J Lipid Res. 2009 Apr;50 Suppl:S172-7 – reference: 22716983 - N Engl J Med. 2012 Jun 21;366(25):2425; author reply 2426 |
| SSID | ssj0004605 |
| Score | 2.6006136 |
| Snippet | Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function... Summary Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that... Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that... Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 60 |
| SubjectTerms | Adult Biological and medical sciences Cardiovascular disease Cardiovascular diseases Cholesterol Cholesterol, LDL - blood Cholesterol, LDL - drug effects Dose-Response Relationship, Drug Drug dosages Female General aspects Genetic Therapy - adverse effects Genetic Therapy - methods Genetics Healthy Volunteers Heart Humans Internal Medicine Lipids Male Medical sciences Middle Aged Mutation Nanoparticles Nutrition research Pharmacokinetics Plasma Proprotein Convertase 9 Proprotein Convertases - biosynthesis Proprotein Convertases - blood Proprotein Convertases - genetics RNA Interference RNA, Small Interfering - administration & dosage RNA, Small Interfering - adverse effects RNA, Small Interfering - pharmacology Serine Endopeptidases - biosynthesis Serine Endopeptidases - blood Serine Endopeptidases - genetics Single-Blind Method Statins Studies |
| Title | Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673613619145 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673613619145 https://dx.doi.org/10.1016/S0140-6736(13)61914-5 https://www.ncbi.nlm.nih.gov/pubmed/24094767 https://www.proquest.com/docview/1473891662 https://www.proquest.com/docview/1490714784 https://www.proquest.com/docview/1492652966 https://www.proquest.com/docview/1505327150 https://pubmed.ncbi.nlm.nih.gov/PMC4387547 |
| Volume | 383 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgkxASQnyOwqiMxMMmEdbEH4l5QaNsmmCrpo1Je4vsOGEVJSlNK7H_mj-BO8dNKSodL41a3zkX93y-2He_I-R1onUiIoOnupIF3PIiULDyBKxgItRRnOUOnf9kII8u-KdLcek33GofVjm3ic5Q2yrDPfK9kMd4pCZl9H78I8CqUXi66kto3CabCF2GWh1fxqvyIl2I-yKDZ--8_XEnZLsSUc4C8a-16d5Y1zBiRVPqYpUv-ndI5R9r1OEDct87l3S_0YaH5FZePiJ3Tvzx-WPyq8EqplVBdUnPBvsU0SImPuWP2snsK61KCj4hra9LuNTDGolBEIfnMCypi1IHj70GkpmZDkfDGl6tv-U_oQ23c6miO6f9889qF25hXVcZZkaWHp4XuwOtn32nxx-PKdpeB9VQjUAU2iRlXlM0mSAYeKbvqKYwHrYCdcztG4o7G6M8MOAcwzcXUGaqwMfbj5BifIWyhdSVI3lCLg4PvvSPAl_yIcikYNPAaGFDI2TCEqkSXgirCjArRS8sDLcFi7RRxiipGPhNKk8SI8JCiZ41PZn3hGFPyUZZlfkzQjUTPWaNiqBDnulIR1YjVhCTmUZ40g7h8z87zTweOpblGKUrAt9CljodSUWHvG3Zxg0gyE0Mcq5J6TzbFexzCkvWTYzxKsa89lamTsO0jtJew43MIXOswJm0nN6Rahyk_7lpd0nZ22fEKmZSYd_bc-1PF4K0k7NDXrXNoBl4-qTLvJohjcJkuTjha2kiiZEAcg2NwGImMVw6ZKuZdAshcbciljEM3dJ0bAkQTH25pRxeOVB1zuDNncfP1z_eC3IXPGbu9uD4NtmYTmb5S_BKp6brTA98Jv2wSzY_HAxOz34Dzo6K-A |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELbGkAAJId4pjGEkkDZpYU38khgJoalj6mg7IbZJ-xbsvLCKkpSmFfRP8dv4Cdw5L6OobHzZp6j1neMk57uzffccIS8CrQPhGTzVlczhMU8dBZbHYSkTrvb8KLHo_IMD2T3m70_EyQr5WefCYFhlrROtoo7zCPfIt13u45GalN7b8TcHq0bh6WpdQqMUi14y_w5LtuLN_i5835eet_fuqNN1qqoCTiQFmzpGi9g1QgYskCrgqYhVCpKbtt3U8DhlnjbKGCUVA9OskiAwwk2VaMemLZO2MAz6vUKucgZTEzPTO-6yPEwbUn-WMbR92Py54bJNiahqjviXLbw51gV8obQsrbHM9_07hPMPm7h3m9yqnFm6U0rfHbKSZHfJtUF1XH-P_CqxkWmeUp3Rjwc7FNEpJlWKIY0ns880zyj4oLSYZ3AphgUSw0AsfsQwozYqHlYIBZDMzHQ4GhawlP-S_IA23D6mim586Bz21CbcIrZdRZiJmVVwwNgdzLLZV9rf7VPU9RYaIh_BUGiZBDqnqKJhYOAJv6aawvuIcxD_JN6iuJMyShwDzjj8sgFsJneq-P4RUoxPcWwuteVP7pPjSxGGB2Q1y7PkEaGaiTaLjfKgQx5pT3uxRmwiJiONcKgtwuuPHUYV_jqWARmFSwLtXBZaGQlFi7xq2MYlAMlFDLKWpLDOrgV7EIKJvIjRX8aYFJVWK0I3LLywXXIjs8ssK3AGDWfluJUO2f_cdH1B2JtnxKppUmHfa7X0h2cDaZRBizxvmkEy8LRLZ0k-QxqFyXl-wM-l8SRGHshzaAQWT_Hh0iIPy0l3NkjcHfGlD69uYTo2BAjevtiSDU8tiDtngS-4__j8x3tGrnePBv2wv3_Qe0JugLfO7f4fXyOr08kseQoe8dSsWzVEyafL1nu_ARGWxNg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELbGkCYkhHinMIaRQNokQpv4JTESQtNKtbEXTYxJ-5bZccIqSlKWVtC_xq_iJ3DnvIyhsvFln6LWd46TnO_O9t1zhLyItI5EYPBUVzKPW555CiyPxzImfB2ESerQ-Xf35OYh_3AkjhbIzyYXBsMqG53oFLUtEtwj7_o8xCM1KYNuVodF7PcH78bfPKwghSetTTmNSkS209l3WL6Vb7f68K1fBsHg_aeNTa-uMOAlUrCJZ7SwvhEyYpFUEc-EVRlIcdbzM8NtxgJtlDFKKgZmWqVRZISfKdGzpifTnjAM-r1GrocsjHCORRv-vJxMF15_lj3UPWj_XPXZmkSENU_8yy7eHOsSvlZWldmY5wf_Hc75h30c3Ca3aseWrleSeIcspPldsrRbH93fI78qnGRaZFTn9OPeOkWkitM63ZDa0-lnWuQU_FFaznK4lMMSiWEgDktimFMXIQ-rhRJIpmYyHA1LWNZ_SX9AG24lU0VX9zcOttUa3MK6rhLMysxraGDsDmbc9Cvd6e9Q1PsOJqIYwVBolRA6o6iuYWDgFb-hmsL7sAVMhdS-orirMko9A445_HLBbKbw6lj_EVKMT3BsPnWlUO6TwysRhgdkMS_y9BGhmokes0YF0CFPdKADqxGniMlEIzRqh_DmY8dJjcWOJUFG8ZygO5_FTkZi0SGvW7ZxBUZyGYNsJCluMm3BNsRgLi9jDOcxpmWt4crYj8sg7lXcyOwzxwqcUctZO3GVc_Y_N105J-ztM2IFNamw7-VG-uOzgbSKoUOet80gGXjypfO0mCKNwkS9MOIX0gQSoxDkBTQCC6mEcOmQh9WkOxsk7pSEMoRXd246tgQI5H6-JR-eOEB3zqJQ8PDxxY_3jCyBxot3tva2n5Ab4LhztxXIl8ni5HSaPgXneGJWnBai5Piq1d5vqxLJDg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+an+RNA+interference+drug+on+the+synthesis+of+proprotein+convertase+subtilisin%2Fkexin+type+9+%28PCSK9%29+and+the+concentration+of+serum+LDL+cholesterol+in+healthy+volunteers%3A+a+randomised%2C+single-blind%2C+placebo-controlled%2C+phase+1+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Fitzgerald%2C+Kevin&rft.au=Frank-Kamenetsky%2C+Maria&rft.au=Shulga-Morskaya%2C+Svetlana&rft.au=Liebow%2C+Abigail&rft.date=2014-01-04&rft.eissn=1474-547X&rft.volume=383&rft.issue=9911&rft.spage=60&rft_id=info:doi/10.1016%2FS0140-6736%2813%2961914-5&rft_id=info%3Apmid%2F24094767&rft.externalDocID=24094767 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673613X60647%2Fcov150h.gif |